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Abstract 
Many complex biological programs are controlled at the level of gene 
transcription by DNA-binding transcription factors.  Recent studies have revealed 
a novel mode of regulation by coactivator proteins, best illustrated by the PGC-1 
family of coactivators.  These factors are highly responsive to a variety of 
environmental cues, from temperature to nutritional status to physical activities, 
and they coordinately regulate metabolic pathways and biological processes in a 
tissue-specific manner.  Notably, the PGC-1 coactivators play a critical role in the 
maintenance of glucose, lipid and energy homeostasis, and are likely involved in 
the pathogenesis of diseases including obesity, diabetes, neurodegeneration, 
and cardiomyopathy.  These actions also raise new opportunities for the 
development of novel therapeutics. 
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Transcription factors function through the docking of specific coactivator or 
corepressor proteins.  While transcription factors bind to DNA in a sequence-
specific fashion, they generally lack the enzymatic activities necessary to modify 
chromatin, unwind DNA and recruit RNA polymerase II.  These biochemical 
activities are the job of coregulators, which usually exist as multiprotein 
complexes in the nucleus, and can be recruited to transcription factors in 
response to cellular signals.  Until recently, most studies of biological processes 
controlled at the transcriptional level have focused on changes in the amounts or 
activities of transcription factors.  While this is undoubtedly a major mode of 
regulation, it has become very clear that transcriptional coactivator proteins can 
be highly regulated and can, in fact, be the primary targets of hormonal control 
and signal transduction pathways (Spiegelman and Heinrich, 2004).  Perhaps the 
best examples of this are the PGC-1 (PPAR Coactivator-1) coactivators.  While 
these proteins were not the first coactivators shown to be highly regulated, their 
regulation and biological function have been studied in greatest detail.  In fact, 
the PGC-1 family of coactivators is emerging as major players that integrate 
signaling pathways in the control of cellular and systemic metabolism.  The role 
of PGC-1 in the regulation of mitochondrial oxidative metabolism and the 
maintenance of glucose, lipid and energy homeostasis will be discussed further 
in this review.  
The first member of the PGC-1 family was identified as a PPAR-interacting 
protein from brown fat, and is now termed PGC-1(Puigserver et al., 1998).  
PGC-1 is the closest homolog of PGC-1 and shares extensive sequence 
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identity (Kressler et al., 2002; Lin et al., 2002a), clustered in several distinct 
domains (Figure 1A), including an N-terminal activation domain (40%), a central 
regulatory domain (35%) and a C-terminal RNA binding domain (48%).  PGC-
related coactivator (PRC) has more limited homology (Andersson and Scarpulla, 
2001), including the activation domain and RNA-binding domain.  Sequence 
analysis reveals that the PGC-1 family of coactivators is conserved in many 
chordate species, including primates, rodents, ruminants, birds, amphibians and 
fishes (Figure 2).  These coactivators have similar domain structure and several 
signature motifs, most notably TPPTTPP and DHDYCQ, that are present in all 
family members.  To date, no clear PGC-1 homolog has been found in lower 
eukaryotes including worm, fly and yeast. 
The PGC-1 coactivators have powerful transcriptional activity when 
covalently linked to a heterologous DNA binding domain (Knutti et al., 2000; Lin 
et al., 2002a; Puigserver et al., 1998), or when they dock on a transcription 
factor.  While they have not been found to encode any histone acetyltransferase 
(HAT) activities in their primary sequence, they bind several powerful HAT-
containing proteins at their N-terminal regions, including CBP, p300 and SRC-1 
(Puigserver et al., 1999).  These proteins acetylate histones and remodel 
chromatin structure to allow access of additional factors for gene activation 
(Figure 1B).  In addition, several proteins encompassing the mediator complex 
(also known as the TRAP/DRIP complex) dock in the C-terminal region of PGC-
1(Wallberg et al., 2003).  These proteins recruit RNA polymerase II and may 
have other activities as well.  The C-terminal region also harbors a Ser/Arg-rich 
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domain and an RNA-binding domain, and has been shown to couple pre-mRNA 
splicing with transcription (Monsalve et al., 2000).  Several studies have shown 
that the PGC-1 transcriptional activator complex is able to displace repressor 
proteins, such as histone deacetylase and small heterodimer partner (SHP), on 
its target promoters, leading to augmented gene transcription (Borgius et al., 
2002; Guan et al., 2005). 
A critical aspect of the PGC-1 coactivators is that they are highly versatile 
and have the ability to interact with many different transcription factors (Table 1); 
in doing so, they activate distinct biological programs in different tissues.  PGC-
1, for example, can bind to and coactivate most members of the nuclear 
receptor family – often in a ligand-dependent manner (such as the ER) but 
sometimes without the addition of a ligand, such as with PPAR(Puigserver and 
Spiegelman, 2003).  Table 1 summarizes transcription factor targets of PGC-
1and  and their respective roles in mediating certain aspects of PGC-1 
function.  Many of these proteins dock in a central region between the N-terminal 
activation domain and the C-terminal SR and RNA-binding domains.  In addition, 
PGC-1 has three functional LXXLL motifs that are used for the binding of many 
nuclear receptors (Knutti et al., 2000; Puigserver et al., 1998).  The fact that 
PGC-1 and  contain distinct binding sites for different transcription factors 
raises the interesting possibility that alleles can be made experimentally, or may 
exist naturally, that can carry out only a subset of functions that the full-length 
proteins can stimulate.  In fact, both PGC-1 and  mRNAs are alternatively 
spliced to generate multiple isoforms, though the functional significance of this 
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remains unknown (Baar et al., 2002; Kamei et al., 2003; Meirhaeghe et al., 
2003). 
Regulation of mitochondrial oxidative metabolism by the PGC-1  
Of the transcription factors that PGC-1 and  coactivate, one subset draws 
special attention; this includes NRF-1, NRF-2, and the nuclear hormone 
receptors, such as PPAR, PPAR, ERR and TR (Table 1).  All of these 
transcription factors directly regulate the expression of certain nuclear-encoded 
mitochondrial genes, and were discussed in greater details in two recent reviews 
(Kelly and Scarpulla, 2004; Puigserver and Spiegelman, 2003).  NRF-1 and 2 are 
themselves targets of PGC-1 (Wu et al., 1999), and are able to stimulate the 
expression of mitochondrial transcription factor A (Tfam), a mitochondrial matrix 
protein essential for the replication and transcription of mitochondrial DNA 
(Clayton, 1991; Parisi and Clayton, 1991; Virbasius and Scarpulla, 1994).  The 
simultaneous stimulation of mitochondrial genes encoded by the two genomes by 
PGC-1 and  leads to increased enzymatic capacity for fatty acid -oxidation, 
Krebs cycle and oxidative phosphorylation (OXPHOS). Importantly, PGC-1 and 
 also induce the expression of genes involved in heme biosynthesis, ion 
transport, mitochondrial translation, and protein import, and can stimulate 
mitochondrial biogenesis and increased respiratory function (St-Pierre et al., 
2003; Wu et al., 1999).  These two coactivators stimulate the biogenesis of 
mitochondria with different metabolic characteristics, reflecting the fact that they 
regulate the expression of overlapping but distinct sets of mitochondrial genes.  
For example, respiration stimulated by PGC-1 is more highly coupled than that 
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induced by PGC-1, when they are expressed in differentiated C2C12 myotubes 
(St-Pierre et al., 2003). Thus, modulating the relative activity of PGC-1 and  
within the cell may lead to fine-tuning of mitochondrial function in response to 
specific metabolic needs.  
Recent studies in PGC-1-deficient mice reveal that although this 
coactivator is dispensable for mitochondrial biogenesis per se, it is absolutely 
required for the normal expression of a large number of mitochondrial genes 
(Leone et al., 2005; Lin et al., 2004).  The mRNA level of these genes is 
quantitatively reduced in all tissues examined to date, including skeletal muscle, 
heart, liver, brown fat and brain.  Interestingly, although PGC-1 shares many of 
its target genes with PGC-1 in gain of function analysis, it is unable to 
completely compensate for the loss of PGC-1 in the normal transcription of 
these genes.  PGC-1 mRNA levels remain unaltered in several tissues from 
PGC-1-null mice. The loss of PGC-1 leads to significant functional deficits in 
oxidative metabolism in multiple tissues and renders mice exercise-intolerant 
(Leone et al., 2005).  Notably, AMP-dependent kinase is constitutively activated 
in skeletal muscle lacking PGC-1, presumably reflecting a state of energy deficit 
(Lin et al., 2004).  These results underscore a critical role of PGC-1 in the 
control of mitochondrial OXPHOS and cellular energy homeostasis.  Whether a 
switch of energy production through enhanced glycolysis occurs in PGC-1-null 
mice remains to be determined.   
Tissue-specific metabolic actions of the PGC-1 coactivators 
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As summarized in Figure 3A, PGC-1 has been shown to regulate adaptive 
thermogenesis in brown fat (Puigserver et al., 1998; Tiraby et al., 2003), hepatic 
gluconeogenesis and ketogenesis (Herzig et al., 2001; Rhee et al., 2003; Yoon et 
al., 2001), and the specification of slow-twitch muscle fibers (Lin et al., 2002b).  
In contrast, PGC-1 controls hepatic lipid synthesis and lipoprotein production 
(Lin et al., 2005).  It is evident that a major feature of PGC-1 function is their 
ability to stimulate the program of mitochondrial biogenesis while simultaneously 
modulating biological processes commonly associated with increased oxidative 
capacity for a particular tissue.  The following sections review PGC-1 function in 
brown fat, liver, skeletal and cardiac muscle and brain, based on gain- and loss-
of-function analysis in cultured cells and in vivo. 
Brown fat  
PGC-1 was discovered as a molecular switch that turns on several key 
components of the adaptive thermogenic program in brown fat (Puigserver et al., 
1998), including stimulation of fuel intake, mitochondrial fatty acid oxidation and 
heat production through expression of uncoupling protein-1 (UCP1).  The 
expression of PGC-1 is rapidly and strongly induced by cold exposure.  Ectopic 
expression of PGC-1 is sufficient to promote differentiation toward the brown fat 
lineage, as shown by activation of UCP1 expression (Puigserver et al., 1998), 
even in human cells (Tiraby et al., 2003).  Notably, mice deficient in PGC-1 are 
extremely cold-sensitive (Leone et al., 2005; Lin et al., 2004).  This is due to 
defective thermogenesis, likely caused by impaired mitochondrial programs for 
fatty acid -oxidation and electron transport, accompanied by reduced induction 
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of UCP1 and deiodinase 2 in brown fat.  Despite this, PGC-1 appears to be 
dispensable for brown adipocyte differentiation per se.  One possibility is that 
PGC-1, which is induced during brown fat cell differentiation (Lin et al., 2002a), 
may play a fundamental role in the development of brown adipocytes. 
Liver  
The expression of PGC-1 and  is induced in the liver at birth and in the 
adult liver following a short period of fasting (Lin et al., 2003; Yoon et al., 2001).  
The transition from fed to fasted states involves drastic metabolic changes in the 
liver to facilitate the adaptation of organisms to nutrient deprivation; these 
changes include activation of gluconeogenesis, fatty acid -oxidation and the 
synthesis and secretion of ketone bodies.  A shift in fuel usage from glucose to 
fats and ketone bodies by peripheral tissues is critical for the maintenance of 
systemic glucose homeostasis and survival of organisms in the period of food 
shortage.  Studies in cultured hepatocytes and in vivo have demonstrated that 
PGC-1 is sufficient to activate nearly all aspects of the hepatic fasting response, 
including gluconeogenesis, fatty acid -oxidation, and ketogenesis.  It does so by 
coactivating key hepatic transcription factors, such as HNF4, PPAR, GR and 
FOXO1, and directly stimulating transcription from their target promoters 
(Puigserver et al., 2003; Rhee et al., 2003; Yoon et al., 2001).  In contrast to 
PGC-1, PGC-1 has a minimal effect on the expression of gluconeogenic 
genes, though this factor also potently enhances the expression of genes 
involved in fatty acid oxidation and ketogenesis (Lin et al., 2003).  The required 
role of PGC-1 in the control of hepatic gluconeogenesis has been revealed by 
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RNAi knockdown experiments in vivo and in genetic studies using PGC-1 
knockout mice (Koo et al., 2004; Lin et al., 2004).  PGC-1 deficiency clearly 
impairs gluconeogenic gene expression and hepatic glucose production, and 
leads to fasting hypoglycemia. In addition, mice lacking PGC-1 develop hepatic 
steatosis upon fasting (Leone et al., 2005). The physiological role of PGC-1 in 
the regulation of the hepatic fasting response remains under investigation. 
Recent studies have implicated PGC-1 as a key regulator of hepatic 
lipogenesis and lipoprotein secretion in response to dietary intake of saturated 
fats (Lin et al., 2005).  Here, the expression of PGC-1 is strongly induced by 
dietary fats in the liver, likely through direct regulation by fatty acids in 
hepatocytes.  PGC-1 docks and coactivates the SREBP and LXR families of 
transcription factors, coupling triglyceride and cholesterol synthesis, lipoprotein 
transport and VLDL secretion.  SREBPs are key transcription factors that control 
the expression of many genes that regulate fatty acid, triglyceride (Kim and 
Spiegelman, 1996; Tontonoz et al., 1993), and cholesterol biosynthesis (Brown 
and Goldstein, 1997), while LXRs are important in the control of lipoprotein 
secretion.  The crucial role of PGC-1 in mediating the link between 
hyperlipidemia and saturated fat intake was demonstrated by RNAi knockdown 
studies in the livers of mice. Thus, the PGC-1 signaling pathway provides a 
plausible link between consumption of saturated and trans fats, and 
hyperlipidemia, including hypercholesterolemia.    
Although the induction of PGC-1 by dietary fats is robust, the expression of 
most of its mitochondrial target genes is not elevated in response to fat intake.  
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These results raise the interesting possibility that the activities of PGC-1 in the 
regulation of hepatic metabolism is strongly influenced by nutritional status, 
perhaps as a result of hormonal milieu under different physiological conditions.  
Similarly, although PGC-1 has been demonstrated to coactivate a large number 
of transcription factors in various cell types, it is highly unlikely that these 
pathways are simultaneously active in the presence of PGC-1.  The molecular 
basis of this specificity in gene activation remains poorly understood.  It is 
possible that the availability of ligands and posttranslational modification of 
transcription factors and/or the PGC-1 themselves may contribute to the 
promoter selectivity.  This is a very important avenue for further inquiry. 
Skeletal muscle   
The ability of PGC-1 to control multiple pathways in a complex biological 
program is also illustrated in skeletal muscle.  In this case, PGC-1 functions as 
a sensitive “rheostat” that responds to neuromuscular input and the ensuing 
contractile activity.  The expression of PGC-1 is readily inducible by exercise 
training in rodents and humans (Baar et al., 2002; Goto et al., 2000; Norrbom et 
al., 2004).  The subsequent activation of calcium signaling pathways appears to 
play a major role in the stimulation of PGC-1 transcription through calcium-
dependent protein kinases (Wu et al., 2002), which culminate in the activation of 
several transcription factors, such as CREB and MEF2, in a feed forward loop 
(Figure 3B) (Handschin et al., 2003).  Although AMPK has been shown to be 
required for exercise-induced PGC-1 expression (Zong et al., 2002), the 
transcriptional targets of AMPK action on the PGC-1 promoter are still not clear.   
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Ectopic expression of PGC-1 in myotubes stimulates GLUT4 expression 
and mitochondrial oxidative metabolism (Michael et al., 2001).  Importantly, 
transgenic expression of PGC-1 in fast-twitch muscle fibers at or near 
physiological levels leads to activation of genetic programs characteristic of slow-
twitch muscle fibers (Lin et al., 2002b).  The skeletal muscle of these transgenic 
mice is resistant to contraction-induced fatigue, indicating a functional switch of 
muscle fiber types by PGC-1.  Consistent with these gain-of-function studies, 
PGC-1 deficient skeletal muscle is prone to contraction-induced fatigue and the 
knockout mice are exercise-intolerant (Leone et al., 2005).  Again, PGC-1 is 
able to couple the metabolic and contractile arms of muscle fiber specification 
and functionally transforms fast-twitch fibers into more oxidative slow-twitch 
fibers.  It is highly likely that similar regulatory mechanisms also occur in other 
tissues where related cell types acquire different oxidative capacities as they 
undergo terminal differentiation.   
Transgenic expression of PGC-1 under the control of -actin promoter 
leads to mitochondrial biogenesis in skeletal muscle and systemic resistance to 
diet-induced obesity (Kamei et al., 2003).  However, the role of PGC-1 in the 
control of metabolic and contractile phenotype of skeletal muscle fibers remains 
to be ascertained.  
Heart  
Both PGC-1 and  are expressed very abundantly in the heart (Lin et al., 
2002a; Puigserver et al., 1998), an organ with an extremely high and dynamic 
demand for ATP.  Much of this supply comes from the oxidation of fatty acids, 
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though glucose can also be a substrate for mitochondrial oxidation.  To date, the 
role of PGC-1 in cardiac energy metabolism is less well studied, but several 
studies have implicated PGC-1 as a crucial regulator of oxidative metabolism in 
the heart.  PGC-1 mRNA levels are strongly induced in the neonatal heart, 
along with the activation of mitochondrial biogenesis, and the metabolic switch 
from glycolysis to fuel oxidation in cardiac muscle (Lehman et al., 2000).  Forced 
expression of PGC-1 in cultured neonatal cardiomyocytes and in vivo powerfully 
stimulates mitochondrial gene expression and biogenesis (Lehman et al., 2000).  
In fact, very high transgenic expression of PGC-1 in mouse heart leads to such 
robust mitochondrial biogenesis that the contractile apparatus is displaced, and 
dilated cardiomyopathy ensues.  Interestingly, PGC-1-null mice develop early 
symptoms of heart failure, such as activation of a fetal program of cardiac gene 
expression and significant increase in circulating levels of atrial natriuretic 
peptide, a hallmark of cardiac dysfunction (Arany et al., 2005).  Defects in cardiac 
function are most clearly seen when the intact hearts were studied in isolated 
perfusion chambers.  Here, the PGC-1 deficient heart shows a significantly 
lower cardiac reserve in response to electrical or chemical stimulation (Arany et 
al., 2005), and is thus less able to perform work in response to increased 
demand.  Abnormal heart rate and impaired left ventricular function were also 
observed in PGC-1 deficient mice following exercise (Leone et al., 2005). 
Brain  
PGC-1 deficiency leads to certain behavioral abnormalities, including 
profound hyperactivity (Leone et al., 2005; Lin et al., 2004). These behavioral 
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changes are associated with axonal degeneration in the brain, especially in the 
striatum (Lin et al., 2004), a region known to be very important in the control of 
movement.  The molecular basis of this axonal degeneration is not completely 
understood.  Though impaired energy homeostasis and ROS metabolism due to 
defects in mitochondrial function are the most likely causes.  Neurons consume 
large amounts of ATP to maintain their membrane ionic gradient and axonal 
transport, and rely almost exclusively on oxidative metabolism to derive energy 
for this function.  In fact, the most common symptoms of patients with genetic 
mutations of mitochondrial genes are neurological-related, reflecting an 
extremely low tolerance for perturbing OXPHOS in the brain (Schon and 
Manfredi, 2003).  It cannot be ruled out, however, that PGC-1 also regulates 
pathways critical for neuronal function.  In fact, the expression of several 
neurofilament proteins and 2 subunit of sodium pumps is reduced in the PGC-
1-null brain (Lin et al., 2004).  It is not yet clear whether this represents the 
cause or the effect of the obvious brain lesions in the knockout mice.  
PGC-1 and the metabolism of reactive oxygen species 
The mitochondrial electron transport chain is a major site of reactive oxygen 
species (ROS) production in the cell (Lenaz et al., 2002; Lowell and Shulman, 
2005).  Under normal conditions, the balance between ROS generation and 
detoxification is controlled by a set of cellular enzymes including superoxide 
dismutase (SOD), catalase and those involved in glutathione metabolism.  As 
PGC-1 stimulate mitochondrial-based respiration, they also increase the 
expression of SOD and glutathione peroxidase, as well as enzymes responsible 
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for glutathione biosynthesis (St-Pierre et al., 2003).  Thus, certain components of 
the ROS scavenging pathway are linked by the PGC-1 to mitochondrial oxidative 
metabolism, apparently enabling cells to maintain normal redox status in 
response to changing oxidative capacity. In addition, PGC-1 and  stimulate the 
expression of UCP2 and UCP3 (Puigserver et al., 2001; St-Pierre et al., 2003; 
Wu et al., 1999), which dissipate the proton gradient and lower mitochondrial 
membrane potential, a process thought to greatly reduce ROS production by 
mitochondria (Miwa and Brand, 2003).  Hence, the PGC-1 coactivators 
apparently have two related but distinct mechanisms to regulate ROS 
metabolism in cells.   
Reactive oxygen and nitrogen species are capable of transducing cellular 
signals under certain conditions (Soberman, 2003).  However, excess free 
radical production leads to oxidative stress, which causes DNA damage, lipid 
peroxidation and oxidative protein modifications.  It is now clear that ROS 
generation is greatly elevated following certain metabolic perturbation, such as 
ischemia reperfusion of the heart, stroke in the brain, as well as in a wide range 
of disorders including neurodegenerative diseases (Ischiropoulos and Beckman, 
2003).  Given the abnormality seen in the brain and heart of PGC-1 knockout 
mice (Leone et al., 2005; Lin et al., 2004), it is highly likely that the PGC-1 are 
important regulators of ROS metabolism in normal physiological conditions and 
under certain states of oxidative stress.   
Regulation of PGC-1 activity 
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The diverse and potent effects of PGC-1 and  on cellular energy 
metabolism necessitate that their activities are under tight control.  This, in 
theory, can be achieved at the transcriptional and posttranscriptional levels.  In 
fact, PGC-1 protein has a very short half-life (~2.3 hours) and is greatly 
stabilized following phosphorylation at three sites (T262, S265, and T298) by p38 
MAP kinase (Puigserver et al., 2001).  These modifications also enhance the 
transcriptional activity of PGC-1 by displacing p160 myb-binding protein 
(p160MBP), a strong transcriptional suppressor (Fan et al., 2004).  The binding of 
p160 may largely account for the suppressive activity residing in the central 
domain of PGC-1. 
Another protein that has been shown to modulate PGC-1 activity is SirT1, 
the mammalian homolog of the yeast Sir2.  SirT1 associates with PGC-1 in the 
central regulatory region between amino acids 200-400 and deacetylates PGC-
1, leading to enhanced transcriptional activity in a NAD+-dependent way 
(Rodgers et al., 2005).  This is particularly interesting because Sir2 regulates 
aging in yeast and other organisms (Blander and Guarente, 2004); aging is a 
process that is affected by metabolic parameters, especially caloric restriction, in 
many species. The ability of SirT1 to bind to PGC-1 and activate it makes a 
direct molecular connection between the pathways that impact organismal aging 
and metabolic regulation.  An important question is whether SirT1 also modulates 
the transcriptional activity of PGC-1 and PRC.   
In addition to post-translational mechanisms, many studies have clearly 
demonstrated that the PGC-1 coactivators are regulated at the transcriptional 
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level in response to a variety of nutritional and environmental stimuli (Figure 3A).  
PGC-1 and  are abundantly expressed in tissues with high energetic need, 
including brown fat, cardiac and skeletal muscle and the central nervous system 
(Kressler et al., 2002; Lin et al., 2002a; Puigserver et al., 1998).  In addition, their 
mRNA levels are subject to substantial regulation by physiological signals within 
these tissues.  For example, PGC-1 mRNA levels are rapidly induced in brown 
fat following cold exposure (Puigserver et al., 1998), and in skeletal muscle in 
response to bouts of exercise (Baar et al., 2002; Goto et al., 2000); PGC-1 
expression remains unchanged under these conditions (Lin et al., 2002a).  In 
contrast, hepatic expression of PGC-1, is stimulated by dietary fat intake and 
thyroid hormone to a much greater extent than PGC-1 (Lin et al., 2005; Weitzel 
et al., 2003).  The expression of both of these coactivators is increased in the 
neonatal liver and heart, correlating with a dramatic expansion of oxidative 
capacity in these tissues during early postnatal development (Lehman et al., 
2000; Lin et al., 2003).  PGC-1 and  mRNA levels are relatively low in adult 
liver in the fed state, however, they are readily inducible upon brief fasting (Lin et 
al., 2002a; Lin et al., 2003; Yoon et al., 2001).    
Although the expression of PGC-1 is not regulated by cold exposure, its 
mRNA level is increased during differentiation of cultured brown and white 
adipocytes (Kamei et al., 2003; Lin et al., 2002a).  While the role of PGC-1 in 
adaptive thermogenesis has been firmly established, the function of PGC-1 in 
the regulation of development and function of adipocytes remains unexplored.  
Interestingly, the expression of PRC in cultured fibroblasts is inducible by serum 
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treatments and is regulated in a cell-cycle dependent manner that peaks during 
the G0-to-G1 transition (Andersson and Scarpulla, 2001). Thus, it is now clear 
that the expression of this entire family of coactivators is under control by distinct 
extracellular signals, consistent with the fact that they modulate different aspects 
of metabolism and other biological processes in the cell.   
Activation of the cAMP signaling pathway is a major mechanism underlying 
the induction of PGC-1 in several different cell types.  In fact, the proximal 
promoter of PGC-1 contains a functional CREB binding site that is required for 
cAMP response (Herzig et al., 2001).  CREB integrates multiple signaling 
pathways in various cell types, including glucagon action in the fasted liver 
(Herzig et al., 2001), calcium signaling through calcium/calmodulin-dependent 
protein kinase IV and calcineurin A in exercised skeletal muscle (Handschin et 
al., 2003; Ojuka et al., 2003) and adaptive thermogenesis in brown fat 
(Puigserver et al., 1998).  Stimulation of activating transcription factor 2 (ATF2) 
by p38 MAP kinase has also been shown to modulate the induction of PGC-1 in 
brown fat by cold (Cao et al., 2004).  In states of low energy, PGC-1 can also 
be induced by the AMP-dependent protein kinase (AMPK) in skeletal muscle and 
subsequently increase energy levels by boosting oxidative metabolism (Irrcher et 
al., 2003; Suwa et al., 2003; Terada et al., 2002; Zong et al., 2002). In contrast, 
cyclin-dependent kinase 9 suppresses the expression of PGC-1 and 
mitochondrial function in the heart, leading to the development of 
cardiomyopathy (Sano et al., 2004).     
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Intriguingly, some transcription factors that are coactivated by PGC-1 can 
simultaneously serve as regulators of PGC-1 transcription.  This is best 
illustrated by the regulation of PGC-1 expression by MEF2 in skeletal muscle 
(Czubryt et al., 2003; Handschin et al., 2003).  The presence of such 
autoregulatory loops provides a molecular mechanism to sustain PGC-1 
expression following physiological stimuli, as in the case of endurance exercise 
(Figure 3).  It seems likely that similar mode of regulation also occurs for the 
thyroid hormone receptor in muscle and liver (Irrcher et al., 2003) and 
glucocorticoid receptor in liver (Yoon et al., 2001).   
 
PGC-1 and metabolic diseases 
It is apparent now that the PGC-1 family of coactivators is highly responsive 
to environmental stimuli and nutritional states of an organism.  These 
coactivators transduce physiological and/or environmental signals and modulate 
programs of gene expression in a tissue-specific manner.  The major activities of 
PGC-1 and  studied to date have been in the modulation of glucose, lipid and 
energy metabolism, enabling the organisms to adapt to their fluctuating 
nutritional status and environmental conditions.  This adaptation to a variety of 
environmental challenges, from temperature to nutritional changes, to alterations 
in physical activity, seems to be a raison d’etre for the PGC-1 coactivators.  
Abnormal PGC-1 activities might alter metabolic properties of tissues and lead to 
various diseases with underlying dysregulation of metabolism, or alternatively, 
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allow certain cells to thrive in their unique tissue environment, such as during the 
progression of cancer. 
Since the PGC-1 coactivators regulate multiple aspects of glucose, lipid and 
energy metabolism, it is not surprising that dysregulation of these proteins has 
been observed in several pathological conditions.  PGC-1 mRNA levels are 
elevated in the liver of rodents of both type 1 and type 2 diabetes; this is likely 
due to alterations of the insulin/glucagons axis and hepatic insulin resistance, 
respectively (Herzig et al., 2001; Yoon et al., 2001).  Increased PGC-1 activity 
clearly contributes to elevated hepatic glucose output and the development of 
hyperglycemia.  In fact, acute knockdown of PGC-1 in liver improves hepatic 
insulin sensitivity and glucose tolerance in db/db mice (Koo et al., 2004).  Thus, 
modulating PGC-1 activity in the liver may have important implication for 
systemic glucose homeostasis.  PGC-1 stimulates gluconeogenic gene 
expression through coactivation of GR, FOXO1, and HNF4.  It is tempting to 
speculate that chemical compounds that selectively disrupt the docking of PGC-
1 to these gluconeogenic transcription factors may provide a novel therapeutic 
modality for the treatment of hyperglycemia (Barthel and Schmoll, 2003).  
Similarly, disruption of PGC-1 docking on SREBP and LXR may specifically 
lead to suppression of the lipogenic and hyperlipidemic activities of PGC-1 in 
liver.  This has been demonstrated as a proof of principle that compounds can be 
developed to target the interaction between GR and PGC-1, but not its 
interaction with other coactivators such as GR-interacting protein (Coghlan et al., 
2003). 
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Insulin resistance is a major pathogenic factor for the development of type 2 
diabetes.  Recent evidence clearly points to a strong association between insulin 
resistance and mitochondrial dysfunction in skeletal muscle (Lowell and 
Shulman, 2005).  The expression of a large set of OXPHOS genes is 
quantitatively reduced in skeletal muscle from type 2 diabetic patients and 
insulin-resistant prediabetic individuals (Mootha et al., 2003; Patti et al., 2003).  
This is accompanied by a significant decrease in the mRNA levels of PGC-1, 
PGC-1 and NRF1 (Patti et al., 2003), and abnormal mitochondrial morphology 
(Kelley et al., 2002).  Importantly, a single nucleotide polymorphism (Gly482Ser) 
in human PGC-1 has been associated with insulin resistance and susceptibility 
to type 2 diabetes in some populations (Ek et al., 2001; Hara et al., 2002; 
Lacquemant et al., 2002; Muller et al., 2003).  Impairment of mitochondrial 
oxidative metabolism has also been observed in age-related insulin resistance 
(Petersen et al., 2003).  Despite these strong associations, it is not clear whether 
reduced PGC-1 expression and impaired mitochondrial OXPHOS is a causal 
factor in the development of insulin resistance and type 2 diabetes.  It is 
interesting to note that the expression of PGC-1 and  is induced in skeletal 
muscle in response to insulin (Ling et al., 2004).  Hence insulin resistance per se 
may lead to reduced PGC-1 expression and mitochondrial dysfunction, which 
may in turn aggravate insulin resistance, resulting in a deleterious spiral.  It is 
tempting to speculate that elevating the activity of PGC-1 in skeletal muscle 
might provide beneficial effects on muscle metabolism and insulin sensitivity.  
Toward this end, compounds targeting the expression of PGC-1 and/or docking 
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of PGC-1 on certain transcription factors, such as ERR, PPAR and NRF, should 
be developed and tested.  
The regulation of PGC-1 expression in the heart suggests a role for this 
protein in the control of fuel utilization, particularly the switch from glucose to fatty 
acid oxidation in neonatal development and under physiological stresses, such 
as fasting (Huss and Kelly, 2004).  PGC-1 mRNA levels are elevated in the 
myocardium of streptozotocin-treated and db/db mice (Finck et al., 2002), 
suggesting that this coactivator may play a role in the development of diabetic 
cardiomyopathy.  Recent studies indicate that PGC-1 deficient heart has 
impaired oxidative energy generation and decreased contractile function, 
suggesting that PGC-1 is required for energy homeostasis in cardiac muscle.  
The expression of PGC-1 is reduced in animal models of heart failure caused 
by pressure overload or ischemia, along with PPAR and genes involved in fatty 
acid oxidation.  These results would argue that the decrease of PGC-1 mRNA 
in heart may represent a maladaptive response that eventually leads to energetic 
failure and cardiac dysfunction.  Similar to the situation in skeletal muscle, 
enhancing PGC-1 activity in cardiac muscle may boost cellular oxidative 
metabolism and improve contractile function of heart.  In addition, PGC-1 has 
been shown to protect cardiomyocytes from apoptosis (Sano et al., 2004), 
suggesting that there may be additional therapeutic benefit for activating the 
PGC-1 pathway in various forms of cardiomyopathy and congestive heart failure. 
Clearly, abnormal PGC-1 activity is likely to play an important role in the 
pathogenesis of hyperglycemia, insulin resistance, and cardiomyopathy.  It 
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remains to be determined whether dysregulation of the PGC-1 is also present in 
other disorders associated with impaired mitochondrial OXPHOS and increased 
oxidative stress, most notably, in various forms of neurodegenerative disease.  
More importantly, the PGC-1 pathways offer novel targets for potential 
therapeutic intervention.  It can be expected that the modulation of coactivator 
docking on their specific binding partners will provide opportunities to selectively 
stimulate or suppress certain pathways, hence obtaining desirable physiological 
effects.  The development of ligands for nuclear receptors which can selectively 
recruit certain coactivators has already been demonstrated (Coghlan et al., 
2003). Thus, new classes of valuable drugs may be in the offing. 
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Figure Legends 
 
Figure 1. Structure and function of the PGC-1 family coactivators. 
(A) Sequence homology of PGC-1, PGC-1 and PRC.  Note that activation 
domain (red), Arg/Ser-rich domain (yellow), and RNA-binding domain (purple) 
are present in all three PGC-1 family members.  PGC-1 and PGC-1 share an 
additional domain of similarity in the central region. 
(B) Protein complexes associated with PGC-1.  PGC-1 binds to the HAT and 
TRAP/DRIP/Mediator complexes at the amino and carboxyl termini, respectively.  
SirT1 and p160 bind to the repression domain, which also contains three p38 
MAP kinase phosphorylation sites.  LXXLL and LLXXL denote nuclear receptor 
binding sites. 
 
Figure 2. Conservation of the PGC-1 family of coactivators in vertebrates.  
Amino acid sequences of the PGC-1 family of coactivators currently available in 
the GenBank database are aligned using the Clustal program.  The relative 
distance represents the degree of sequence identity among different members.  
Note that the absence of certain members in some species is likely due to the 
lack of full-length cDNA sequences in available databases. 
 
 
 
Figure 3. Biological activity and regulation of PGC-1. 
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(A) Tissue-specific function of PGC-1 and .  PGC-1 regulates adaptive 
thermogenesis in brown fat, muscle fiber specification, and hepatic fasting 
response, while PGC-1 coordinates lipogenesis and lipoprotein secretion in liver 
in response to dietary fats.   
(B) Regulation of PGC-1 expression in skeletal muscle and mechanisms by 
which PGC-1 stimulates mitochondrial gene expression.  Coactivation of MEF2 
by PGC-1 provides a positive feed-forward signal to rapidly induce PGC-1 
expression following muscle contraction.  PGC-1 induces the expression of 
ERR, which activates the expression of NRF1, NRF2 and ERR itself.  These 
molecular events lead to the stimulation of nuclear-encoded mitochondrial genes. 
PGC-1 also simultaneously regulates the expression of slow-twitch muscle fiber 
genes through coactivation of MEF2. 
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Table 1. Transcription factor targets of the PGC-1 family of coactivators. 
Transcription factor     PGC-1α   PGC-1β  Function   References 
 
NRF1 
NRF2  
PPARα    
PPARβ/δ  
PPARγ   
ERRα,β,γ   
 
TRβ   
LXRα,β   
FXR  
GR 
ERα,β  
PXR 
Sox9  
MEF2  
FOXO1  
HNF4α  
SREBP1a, 1c, 2 
+      +  mitochondrial genes Wu et al., 1999 
+   ND  mitochondrial genes Mootha et al., 2004 
+     +   fatty acid oxidation  Vega et al., 2000 
+   ND  fatty acid oxidation  Wang et al., 2003 
+    +  UCP1/GyK induction Guan et al., 2005; Puigserver et al., 1998 
+    +  mitochondrial genes Kamei et al., 2003; Mootha et al., 2004;  
Schreiber et al., 2004 
+    +  cpt1 induction  Wu et al., 2002; Zhang et al., 2004b 
+    +  lipoprotein secretion Lin et al., 2005; Oberkofler et al., 2003 
+   ND  triglyceride metabolism Zhang et al., 2004a 
+    −  gluconeogenesis  Kressler et al., 2002; Yoon et al., 2001 
+    +  unknown   Kressler et al., 2002 
+   ND  unknown   Bhalla et al., 2004 
+   ND  chondrogenesis  Kawakami et al., 2005 
+   ND  slow fiber genes  Lin et al., 2002b; Michael et al., 2001 
+    −  gluconeogenesis  Puigserver et al., 2003 
+   +/−   gluconeogenesis  Lin et al., 2002a; Yoon et al., 2001 
−    +  lipogenesis/   Lin et al., 2005 
   lipoprotein secretion 
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